Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Solution for Injection 50 ml x 2 mg/ml |
|
Related information
Dosage
See prescribing information for full details.
Indications
For the treatment of a wide spectrum of neoplastic diseases including breast carcinoma, lung carcinoma high doses, ovarian carcinoma, gastric carcinomas, soft tissue sarcoma. Intravesical administration of epirubicin has been found to be beneficial in the treatment of superficial bladder carcinomas and in the prophylaxis of recurrences after transurethral resection. I.V. administration for the treatment of advanced bladder carcinoma.
Contra-Indications
By I.V. route: Known hypersensitivity to epirubicin. Severe bone marrow depression following previous chemotherapy and/or radiotherapy. Patients already treated with anthracyclines such as doxorubicin or daunorubicin up to the relevant maximum cumulative dose. Acute infections and existing inflammation of the buccal and/or GI mucosa. Progressive heart failure, arrhythmia and conductive disorders with serious hemodynamic effects, acute inflammatory myocardial conditions, unstable angina pectoris, acute myocardial infarction or myocardial infarction within previous 6 months, cardiomyopathy.By intravesical route: Should not be given by intravesical instillation for the treatment of invasive tumors penetrating the bladder wall.
Special Precautions
See prescribing information for full details.
Side Effects
Myelosuppression and cardiotoxicity, nausea, vomiting and mucositis, reversible alopecia.
See prescribing information for full details.
Drug interactions
Heparin, anticytostatic agents, alkaline solutions. For list of compatible diluting solutions – see prescribing information for full details.
